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AN AHP APPROACH FOR BALANCING EFFICIENCY AND EQUITY IN THE 
UNITED STATES LIVER TRANSPLANTATION SYSTEM: A PILOT STUDY 
Vijayachandran M. Veerachandran 
ABSTRACT 
 
 Liver transplantation and allocation has been a controversial issue in the United 
States for decades. One of the main concerns in the allocation system is the trade-off 
between the two main objectives, efficiency and equity. Unfortunately, it is difficult to 
reach consensus on how to develop allocation policies that aim at balancing efficiency 
and equity, among transplantation policy makers, administrators, transplant surgeons and 
transplant candidates. 
Our research identifies and classifies the outcomes of liver allocation into two 
major categories, efficiency and equity, that are, often times, conflicting. Previous 
researchers did not consider how to balance outcomes in these two categories. Our 
research uses Analytic Hierarchy Process, a Multi-Criteria Decision Analysis 
methodology, to build a framework that quantifies the decision-making process and help 
decision makers to reach a valid consensus in terms of balancing these outcomes. Latest 
available patient registration and follow-up data are used in data analysis. Results from 
 vi
This research addresses the deficiencies of the current liver transplantation policy 
and is intended to refine the policy that will result in a more balanced allocation system 
with respect to efficiency and equity. Our proposed methodology can be applied to 
incorporate further changes in policy selection and refinement. 
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CHAPTER 1  
INTRODUCTION 
 
1.1 Current Health-Care Scenario in the United States 
Improved public health policy and improvements in medical care have increased 
the life expectancy of the average American from 49 years in 1900 to an all time high of 
77.4 years in 2002 [1]. More amounts are spend for health-care awareness and 
improvement. The United States remains the leading nation in global healthcare 
spending: an average of $ 4,500 per person [2]. On a per capita basis, health spending in 
the U.S. is 50% higher than in the second-highest spending country, Switzerland, 
according to the Organization of Economic Co-operation and Development (OECD) 
figures [3]. In 2005 the U.S. healthcare industry grew as a more demanding population 
sought the best healthcare they could afford. The Center for Medicare and Medicaid 
Services (CMS) reports that health care expenditure in the United States is expected to 
continue growing to 16.2% of the Gross Domestic Product (GDP) in 2005, up from 16% 
in 2004 [4] [7]. By 2015 health care expenditure in the United States is projected to reach 
$4 trillion and contributes to 20% of the GDP [5]. This makes the health-service industry 
the largest in the U.S. The aforementioned data suggests that even a small improvement 
in health-care or associated services might have significant effect on the overall economy 
and life expectancy.  
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 World Health Organization (WHO) statistics show that the U.S. ranks 37th out of 
191 countries in performance metrics for overall levels of population health, system 
responsiveness, health inequalities or disparities among the population and distribution of 
the financial burden [6]. In 2005, the costs of health insurance premiums continued to rise 
in the U.S., rising costs are likely to affect the country's healthcare industry [7]. The U.S. 
Census Bureau stated that 46 million Americans now lack health insurance. Expenditure 
on health services more than doubled in 2005 from ten years earlier. Rising costs of a 
health insurance is a growing concern; more and more people are living without adequate 
health insurance, Nearly 46 million people in U.S. have no health insurance, which 
means these individuals will be deprived of proper treatment solutions in times of 
necessity [8]. 
 The Business Communication Company (BCC) reports that more than half of the 
health care expenditure in the United States are for organ failures or tissue loss, an 
amount that exceeds $600 billion [9]. They also reported that over 215,000 people die in 
the U.S. every year from diseases that are treatable with transplantation. The National 
Foundation for Transplants reports the average cost for a kidney transplant ranges from 
$75,000 to $100,000, liver transplants from $250,000 to $275,000 and lung transplants 
from $200,000 to $250,000. The U.S. Organ transplantation was a $4.2 billion market in 
2002 of which 76% is attributed to kidney and liver transplantation. The market is 
projected to grow at a rate of 5% to $5.4 billion by 2007 [9]. 
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1.2 Organ Allocation in the U.S. 
An organ transplant is the transplantation of a whole or partial organ from one 
body to another, for the purpose of replacing the recipient's damaged or failing organ 
with a functioning one from the donor. Organ donors can be living, or cadaveric. In the 
United States, there's a great shortage of donor organs: hearts, livers, lungs, kidneys, 
pancreases and small intestines. Even though there is an increase in the number of 
transplants and available livers for transplantation, there is wide disparity between the 
number of organs needed for transplantation and number of organs available. Over 
92,000 Americans are currently waiting for an organ transplant at any given day, and this 
number is increasing and is expected to reach 100,000 by the end of 2010 [10]. In 2005, 
only about 28,000 organ transplants were performed. On average, 114 people are added 
to the nation's organ transplant waiting list each day -- one every 13 minutes. Nearly 
6,500 people died in 2005 because no organs were available.  
 Lack of available donors in this country lead to the death of 3,886 kidney patients, 
1,811 liver patients, 457 heart patients and 483 lung patients in 2004 while waiting for 
life-saving organ transplants. Almost 10 percent of the patients currently waiting for liver 
transplants are young people under 18 years of age. On November 30, 2001, 2,348 
children under age 18 were registered on the organ transplant waiting list. Candidates for 
kidney transplants top the waiting list followed by liver candidates and lung candidates 
published by the United Network for Organ Sharing (UNOS), 
 Our research focuses on the study of liver transplantation. Liver transplantation 
remains the only treatment for end-stage liver disease (ESLD); however the number of 
patients who could benefit from a transplant far exceeds the number of available 
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cadaveric donors. There is a wide disparity in the allocation of organs based on various 
characteristics for example patients with type O blood wait the longest for a liver 
transplant--an average of 1,243 days [13]. People with type AB wait the shortest time--an 
average of 210 days. Waiting time has clinically and statistically significant effect on the 
probability of graft failure outcomes following transplantation. For every fifty days of 
wait time on the list for a transplant the probability of graft failure at one year increases 
in between 1% and 2%. 
 
1.2.1 United Network for Organ Sharing  
The United Network for Organ Sharing (UNOS) manages the nation's organ 
transplant system and oversees a comprehensive database of clinical transplant 
information under a contract with the federal government. UNOS maintains and operates 
the computerized organ sharing system by matching donated organs to patients registered 
on the national organ transplant waiting list. UNOS seeks to increase organ donation 
through the education of the public to the dire need of organ transplants and the 
improvement of transplant success rates through outcomes-based research and 
policymaking [14]. The strength of the transplant database relies on the active reporting 
of 412 UNOS member institutions. 
 
1.3 Liver Transplantation 
 Liver transplantation is necessary for the cure of most causes of acute or chronic 
liver disease. Liver transplantation is appropriate to any acute or chronic condition 
resulting in irreversible liver dysfunction, provided that the recipient does not have other 
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circumstances that will preclude a successful transplant. Cirrhosis is the main reason for 
more than 80% of transplantations performed in adults, (hepatitis C and alcoholic liver 
disease are the two most common diagnoses). According to (UNOS), there are more than 
17,000 patients on the national waiting list for a liver transplant. Yet, in 2002, only 5,329 
liver transplantations were performed [14]. The large disparity between the number of 
available deceased donor organs and qualified recipients awaiting liver transplantation 
has created ongoing debate about selection criteria, the timing of transplantation, and 
attempts to expand the donor pool as a result of increasing mortality rates among listed 
patients. 
 
1.3.1 Research Motivation  
 UNOS data shows that 10 percent of the waiting population dies before a liver is 
available [14]. Unfortunately liver transplantation ranks among the most expensive 
medical services and costs hundreds of thousands of dollars [16]. The existing system of 
liver allocation gives more preference to patients living near donor, (i.e. more emphasis is 
placed on geography than trying to ensure urgency). Only organs which are not suited 
within an Organ Procurement Organization (OPO) is given out for regional allocation and 
later if there is no match found in the region is offered nationally. There is very little 
rationale explaining the reason behind this.  
The existing system takes into account of medical factors including waiting time 
and HLA level medical severity calculated using Model For End Stage Liver Disease 
(MELD) score and blood compatibility [21]. Efficiency is more and more emphasized in 
the existing policy and little effort is given to make the system equitable in terms of 
 6
geography, race gender and others, As a result the system that fails to address the equity 
issues associated. 
The risk of death among women, Asians, Hispanics and children are more than 
that of rest of the population due to a longer waiting time for transplant than foreign 
nationals and repeat transplant patients [17]. There exists a wide disparity in waiting 
times across different regional allocation of livers ranging from 31 days to 207 days [18] 
[20].  
 The number of patients registered for transplant doesn’t match with the rapidly 
growing mortality rate associated with shortage of organs. Procured livers remain 
transplantable only for a limited period of time based in the Cold Ischemic Time (CIT) 
normally ranging from 18 – 24 hours [19]. Two most important issues associated with 
allocation delays and maximum utilization of this scarce life saving resource are 1) 
Quality of match and 2) increase in rejection rate. About 10 to 15% of patients die while 
waiting for transplantation. Due to the severe shortage of livers, an increase in the quality 
of the allocation procedure and policy is critical for ESLD patients.  
 
1.3.2 National Organ Transplant Act 
The responsibility of the Organ Procurement and Transplantation Network 
(OPTN), formed by the National Organ Transplant Act (NOTA) of 1984, ensures the 
national registry of organ transplants is established with an emphasis on the development 
of equitable and efficient organ allocation policies [22]. NOTA asserts that a proper 
system to allocate donated organs for transplantation among transplant centers and 
patients should be ranked according to established medical criteria. The Senate Labor and 
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Human Resources Committee amended NOTA with the following: an equitable system is 
necessary such that individuals throughout the country can have equal access to organ 
transplantation when appropriate and necessary [22]. The allocation of transplantable 
organs has been the subject of considerable debate throughout the transplant community 
during the last decade [23]. A debate which reached congress in 1998 remains unsettled 
since then.  
The UNOS is responsible for managing the national organ donation and allocation 
system. The current allocation procedure was approved for implementation on February 
28, 2002 [14]. In the last six years there has been four changes in policy [24]. These 
multiple changes highlight the challenge in forming a consensus on allocation policy. 
 
1.3.3 Efficiency and Equity in Liver Allocation 
 The goal of a proper allocation policy is to identify a system which is equitable 
and efficient. In an equitable system, each individual on a transplant waiting list has an 
equal opportunity to receive a transplant subject to established medical and demographic 
criteria. No discrimination or privilege for one patient over another based on region, 
ethnicity etc. Efficiency implies the diminution of the wastage of donated livers available 
for transplantation. Equity in our research is measured in terms of the difference over 
efficiency outcomes.  
 
1.4 Analytic Hierarchy Process  
 The Analytic Hierarchy Process (AHP) is capable of combining qualitative and 
quantitative criterions in decision making processes. The AHP model is successful in 
 8
practice and has numerous and diverse applications. AHP’s capability of handling 
complex decision problems is well acknowledged. AHP can handle complex and poorly 
defined problems which rigorous mathematical models display difficulty in solving. AHP 
has the ability to handle mix qualitative and quantitative criteria within the same decision 
framework. It also helps create a consensus of scenarios or situations by converting 
qualitative decisions to quantitative data. AHP has the ability to handle both tangible and 
intangible attributes, define the structure of a scenario through its inherent hierarchical 
model and verify the consistency of end decisions 
 
1.5 Research Contributions  
This research aims to balance the trade-off between efficiency and equity in liver 
transplantation, an issue that is heavily debated. This framework can also be used for 
making similar policies addressing the efficiency and equity tradeoff. The AHP approach 
is used to quantify the decision making process and build logics with complex decision 
making criteria for policy selection. This research addresses the concerns regarding the 
need for a change in allocation policy, which needs to reduce or eliminate inequity in 
organ transplantation system.  
The latest data from UNOS is used in our research. This research uses AHP 
methodology for organ allocation. Even though numerous application of AHP can be 
found in complex medical decision analysis process, as such none of the applications uses 
the capability of AHP in selection and evaluation of organ allocation policies. Our 
research aims to address the concerns in liver allocation policy by tying efficiency and 
equity together, which previous researchers held separate. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Introduction 
This chapter discusses the literature related to the research. In section 2.1 we will 
introduce Analytic Hierarchy Process (AHP), describe several applications, and 
summarize various solution techniques. In section 2.3 we will summarize previous 
studies that apply AHP to medical decision making problems. In section 2.4 will discuss 
previous decision making methodologies in the national liver allocation system. Finally, 
section 2.5 will provide analysis on the previous studies addressing efficiency and equity 
in liver allocation. 
 
2.2 Analytic Hierarchy Process 
 AHP is a multi-criteria decision making tool that is flexible and used across wide 
variety of disciplines. It helps analyze both quantitative and qualitative aspects of a 
decision process. AHP was developed by Thomas L Saaty in 1970 [25]. An advantage of 
AHP over other multi-criteria decision making methods is that the AHP can incorporate 
tangible as well as intangible factors, especially when the subjective judgments of 
different individuals constitute an important part of the decision process. The method is 
widely used in varying areas such as politics, economics, sociology, and even in medicine 
because of the following advantages: 1) this method can handle both quantitative and 
qualitative data all at once; 2) this method uses the eigenvector and eigen-value property, 
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which presents a computational advantage 3) a reduction  in cognitive burden to decision 
makers when comparing with other similar methods and 4) previous works have already 
verified the advantages of this method with numerous case studies.  AHP has broad 
application areas including planning, resource allocation, conflict resolution and 
optimization and selection of the best alternative [26]. This research uses the selection 
approach of AHP: selecting the best alternative from a set of given feasible alternatives. 
AHP utilizes a numeric scale to calibrate the measurement of quantitative as well as 
qualitative performances (Table 2.1), the scale ranges from one to nine with one 
corresponding to least favored and progressively moving up the scale to nine which 
corresponds to very strongly favored.  
 
Table 2.1 The Fundamental Scales (Saaty and Vargas, 2000) 
 
Numerical Score Definition Explanation 
1 Equal Importance Two activities equally  contributes to the objective 
2 Weak  
3 Moderate importance Experience and judgment slightly favor one activity 
over another 
4 Moderate plus  
5 Strong importance Experience and judgment strongly  favor one 
activity over another 
6 Strong plus  
7 Very strong or 
demonstrated importance 
An activity is favored very strongly over another; its 
dominance demonstrated in practice 
8 Very, very strong  
9 Extreme importance The evidence favoring one activity over another is 
of the highest possible order of affirmation 
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2.2.1 Methodology 
 AHP aids in formulating a multi-attribute decision problem in the form of a 
decision tree, where each of the hierarchy level involves a variety of criteria. It can be 
from a simple single level hierarchy to a multiple level (n) hierarchy. AHP addresses the 
decision problem of choosing the best alternative by systematic and quantitative 
comparison of different criteria using pair-wise comparison techniques. Mathematically, 
it determine the weights of the comparison pairs Ci for i = 1 to n’ where n is the number 
of criteria. 
  AHP exceeds the comparative judgment approach by relaxing the normality 
assumption of parameters. In this research, AHP is used in this research to develop and 
analyze trade off between conflicting outcomes in the course of structuring reciprocal 
pair-wise comparison matrices. 
AHP starts by breaking down the problem hierarchically; each level of the 
hierarchy consists of a few manageable elements. These elements are further sorted to 
another set of sub-elements. This process continues until all specific elements of the 
problem are measured, which in turn represents the lowest level of the hierarchy. 
Structuring the problem hierarchically reduces the complex nature of the problem and 
helps identify the major components. It also helps us understand the problem in a better 
manner and sort the trivial and non trivial elements. 
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 2.2.2 An Overview of AHP Applications 
The AHP model has found numerous successful applications. An overview of 
AHP in various areas is presented in Vaidya and Kumar (2004). These applications for 
AHP include decision making in personal, social, manufacturing, politics, engineering, 
education, government and health care applications. The authors reviews several 
approaches used in AHP, selection, evaluation, priority, development, resource 
allocation, decision making, forecasting, medicine [26]. 
 In a review of the 150 top-tier journals, the most popular applications of AHP 
falls either in the combination of engineering application and selection approach or social 
application and selection approach. AHP has been used in many cases as a stand-alone 
application however variations of AHP such as fuzzy AHP or a combination of AHP with 
tools like linear programming, artificial networks and fuzzy set theory makes it more 
versatile and expands the application areas. The application of AHP is also seen a 
increasing trend as more and more top tier research publications like the European 
Journal for Operations Research (EJOR) have special editions and annual symposium for 
AHP being held due its increased application areas. 
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Figure 2.1 AHP Themes 
 
2.3 Selection Theme 
 Forman and Gass (2001) mention several AHP applications in selecting best 
alternatives from a given set of multiple alternatives in a multi-criteria environment. The 
application areas include product selection, vendor selection and policy decision. Their 
paper talks about application of AHP in more than 50 research decision situations within 
the Xerox Corporation; such as portfolio management, engineering design selection, 
technology implementation, market segment prioritization and customer requirement 
prioritizing [27]. Sharp (1987) discusses the application of AHP in their selection of 
lowest cost haulers to handle the dispatches to reduce dispatch costs [29].  
AHP has a significant role in group decision making, Dyer and Forman (2002) 
state the benefits of using AHP in group decision making through decomposition, 
comparative judgment and synthesis of priorities [30]. 
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2.4 AHP in Health-Care 
 
 AHP has been a powerful tool to health care decision makers. Many common 
themes have been found in AHP aided decision making in the health care industry. This 
literature review will mainly discuss the application of AHP in clinical and medical 
decision evaluation. The problems mostly use the selection and decision making 
approach of AHP [26]. Application of resource allocation and prioritization themes can 
be found in a) medical staff decision making b) identifying alternative technologies to 
purchase, c) assisting patients in their decision making process. AHP is not only capable 
of analyzing economic and technical factors in the healthcare industry but also social and 
human factors [31[32] [33].  Hariharan et. al (2005) presents an application of AHP for 
measuring and comparing the global performance in quality of intensive care units [34]. 
Different approaches have been taken in health care decision making problems 
using AHP, as demonstrated in the following two examples. Wu, Lin and Chen (2006) 
apply AHP in optimal selection of locations for Taiwanese hospitals [35]. The model 
addresses the burgeoning health care quality consciousness among Taiwanese residents 
and improves scope of medical services considering a competitive advantage. Rosetti et 
al (2001) address decision problem for hospital deliver systems that addresses economic 
and technical performance as well as social human and environmental factors. The model 
enables a better understanding of delivery and transportation requirements in medium and 
large size hospitals [36]. 
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2.5 AHP in Medical Decision Making 
 Min et. al (1997) propose a model which helps medical clinics improve service 
strategies in the competitive health care industry. Their research uses AHP for the 
comparative evaluation of quality benchmarking in health care service improvement [37]. 
A recent development in technology and bioethics enables an increased participation 
from patients in their own health care decision making, resulting in a shared decision 
making model Singpurwalla et al (1999) [39]. 
 Liberatore et. al, (2003) uses AHP to model a shared decision making among 
patients and physicians for addressing the growing concern of prostate cancer in men. 
The model also successfully captures the decision-counseling protocol for cancer 
screening. The adaptability of AHP in modeling complex problems is emphasized to fit 
the research. The paper describes the methodology in three steps of which the first is 
identifying the alternatives available and personal criteria for evaluation. Secondly 
determining how the alternatives achieve the personal criteria based on analysis thirdly to 
determine the priority of the steps and finally deciding among alternatives. The study 
emphasizes the lack of training needed for patients who are involved in decision making 
and the addresses the necessity of more application of AHP to personal decision making 
[39]. Applications of AHP in medical decision making and medical decision support can 
be found [40 [41] [42]. 
 Cook, Staschak and Green (1990) work on the equitable allocation of livers for 
orthotropic transplantation they consider the major factors to logistics, tissue 
compatibility, waiting time, financial and medical status. They rate the patients in terms 
of main categories based on their rank in subcategories using pair-wise comparisons [33]. 
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They state that the system lacks formal evaluation and is based on the intuition of 
individuals involved. While equity is heavily emphasized, efficiency of the 
transplantation is poorly addressed. Equitable provision and healthcare financing is one 
of the National Health Service’s (NHS) growing concerns since its inception (Sassi et al 
2001). Awareness of widening health equities since the publication of Black report has 
raised equity to a high rank among policy makers.   
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CHAPTER 3 
PROBLEM STATEMENT AND METHODOLOGY 
 
3.1 Introduction 
 Allocating available livers to necessary patients involves a lot of discretion. 
Choosing an optimal liver allocation policy among a set of alternatives is a challenge 
given the subjective nature of this problem. The decision maker may not be able to make 
consistent decisions addressing the efficiency and equity in selecting policy. Decisions 
involved in selecting the best policy must consider various outcomes of liver 
transplantation including efficiency, equity and trade-offs between them [45]. This makes 
the problem a Multi-Attribute Decision Making problem (MADM). AHP is a MADM 
methodology which helps quantify the decision making process and gives decision 
makers the ability to reach a valid consensus in decision making rather than depending 
totally on their intuition [25]. 
 
3.2 Current Liver Allocation System 
  This section provides an overview of the existing liver allocation system. 
Knowledge of the existing system will help in understanding the difficulty faced by 
decision makers in allocating available livers to ESLD patients. UNOS operates the 
national system for organ transplantation. It is responsible for managing and 
administering the proper allocation of available organs for transplantation. The current 
liver allocation system was implemented in February 28, 2002 [20]. The policy has been 
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changed four times in the last six years [21]. Numerous changes in such a small duration 
shows that there is a need for improvement in the liver allocation policy.  
 
3.2.1 United Network for Organ Sharing  
 UNOS is responsible for every organ transplant performed in the United States. 
UNOS supervises the organ donation and procurement via non-profit agencies called 
Organ Procurement Organizations (OPO).  OPOs provide organ recovery services, 
manage the clinical care of the donors, enter donor information into the UNOS computer 
database to find a match and coordinate the organ recovery process to hospitals located 
within designated geographical area in the U.S.  OPO’s also promote organ donation in 
their communities by sponsoring workshops and participating in community health fairs 
and events [14]. 
The national UNOS membership is divided into 11 geographic regions, each 
consisting of several OPOs. This regional configuration was developed to facilitate organ 
allocation and to offer individuals the opportunity to identify concerns regarding 
procurement, allocation, and transplantation of organs that are unique to their region. 
The patients are divided in to two categories PELD and MELD based on the age. 
PELD score is for patients under 18 years of age. In our research we are focused on the 
adult liver allocation procedure. UNOS maintains a patient waiting list that is used to 
determine the transplant candidates among the patients. When a liver becomes available, 
the following factors are considered for its allocation: medical urgency of the patient, 
patients OPO, patient region, patient score from clinical and medical urgency, and patient 
waiting time (Figure 3.1).  
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UNOS provides a framework of principles for making policy decisions about 
organ allocation. Currently the existing systems follow a “sickest first” approach. Patients 
with severe medical urgency will be offered the liver first [47]. 
 
 
Figure 3.1 Schematic Representation of Current Liver Allocation System 
 
Figure 3.1 explains about the current liver allocation procedure. Every liver 
available for transplant is first offered to those Status 1 patients located within the 
harvesting OPO based in descending order of MELD score. If there are no suitable Status 
1 matches within the harvesting OPO, the liver is then offered to Status 1 patients within 
the harvesting region. If a match still has not been found, the liver is offered to all non-
Status 1 patients in the harvesting OPO in descending order of MELD score. The search 
range is again broadened to the harvesting region if no suitable match has been found 
within the harvesting OPO. If no suitable match exists in the harvesting region, then the 
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liver is offered nationally to Status 1 patients followed by all other patients in descending 
order of MELD score [14]. 
 
3.3 Liver Transplantation Issues 
 In the existing liver transplantation policy, more emphasis is given in the 
geography of patient than balancing the equity issues associated with the model. A 
harvested liver is first distributed according to medical condition and then by the 
proximity towards the transplant OPO. This results in wide inconsistency as a patient’s 
chance of living or dead is based on where they live than their medical urgency [20]. The 
condition becomes worse when current policy allow people to list in more than one 
geographical region, known as multiple listing. Many patients who are able to list in more 
than one region stand a higher chance of obtaining a liver than people listed in only one 
region [21]. 
 Any organ allocation policy should satisfy at least the following three 
performance goals: 1) identify and establish standardized criteria for measuring proper 
medical scores for eligibility of transplant patients before adding to the waiting list, 2) 
facilitate a fair comparison of patients across the waiting list. Geographical preference of 
the patients should be widely reduced and more emphasis should be give to the equity 
aspect [50]. A change in the increased emphasis on efficiency should be pushed by 
regulations to encourage a move to a more equitable system. 
There is less rationale in providing a liver to a severe End Stage Liver Disease 
(ESLD) patient irrespective of the survival rate [20].  Two specific and somewhat 
conflicting goals should be considered for decision making in transplantation: efficiency 
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of the transplantation and equity in transplantation [22]. Which one should be given more 
emphasis, fairness surely gives higher preference to equity, but utilization emphasizes on 
higher efficiency. We shall balance the efficiency and equity of these conflicting 
outcomes and reach a more desirable decision making policy. 
 
3.4 Analytic Hierarchy Process 
The AHP method by Saaty is based on two important theoretical principles: the 
fundamental scale for ratio comparison, and the eigenvector and eigen value property 
[25]. Saaty utilizes a fundamental scale ranging from one to nine. The scale has its origin 
on the Weber-Fechner’s sensation (response) equation “Law of stimulus of measurable 
magnitude” (i.e. 0,log ≠+= absaM ) where M denotes the sensation and s the stimulus) 
(Fechner, 1966) [52] [53]. When making pair-wise comparisons, nearest integer 
approximation from the fundamental scales of one to nine is being used. This scale has 
been validated for effectiveness in many applications by numerous individuals through 
the theoretical justification of what scale one must use in the comparison of 
homogeneous elements (Saaty and Vargas, 2000) [54]. The upper limit of nine is adopted 
following Miller (1956)’s “Magical number theory” [55]. Alternatives are compared 
based on this fundamental scales in a pair-wise comparison fashion; then a decision 
matrix is composed [55]. 
 
 
3.5 Illustrative Example 
We are using an example to explain the AHP methodology. There is an age old 
adage which says apples cannot be compared with oranges. Our objective is to choose the 
best fruit from a set of alternatives, including apple, orange and grapes. These can have 
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many criterions in common: color, quality, appearance, seediness, etc. We may prefer an 
orange for color criteria but for appearance criteria an apple and for quality criteria 
grapes. Strength of our preference for these characteristics may vary. Even though we 
may be indifferent to some attributes there will be strong preference for some other 
attributes which may vary across circumstances. 
  The challenge is to identify a set of alternatives which strongly fulfills the goal 
which satisfies entire set of objectives. The decision making is concerned with weighing 
alternatives through pair-wise comparison. 
  
3.5.1 Decomposition and Development of Hierarchy Structure 
 The AHP methodology suggests the development of a hierarchical structure. The 
formulation of a decision hierarchy is a critical step in AHP because it helps to 
effectively frame a problem and simplify the analysis process. It also helps to decompose 
the problem into inter-related decision element goals, attributes and alternatives.  In our 
specific example the hierarchy structure consists of a three-level hierarchy consisting of a 
final objective goal, level of attributes through which these alternatives are being 
evaluated including color, quality, appearance and seediness and  final level of 
alternatives, apple orange or grape to chose from (Figure 3.2). 
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QUALITY APPEARANCECOLOR SEEDINESS
APPLE ORANGE GRAPES
 
Figure 3.2 Evolution of Hierarchy Model for Fruit Selection 
 
3.5.2 Evaluation of Hierarchy 
 The second step in an AHP process is the evaluation of the hierarchy. 
1) Identify the preference weights (judgments) by pair-wise comparison of the 
decision elements. 
 
2) Synthesize the preference weights to determine the most preferred alternative. 
 
Let us consider the elements from C1 , to Cn  of some level in hierarchy. The weights of 
influence W1, to Wn are found on some element in the next level. We will determine the 
pair-wise comparison matrix aij (i, j = 1, 2, n) which indicates the strength of Ci when 
compared with Cj.  The matrix of these numbers aij is denoted A, or 
   
Goal 
Criteria 
Alternatives
 24
⎥⎥
⎥⎥
⎦
⎤
⎢⎢
⎢⎢
⎣
⎡
=
1/1/1/1
1/1/1
1/1
1
321
32313
22312
11312
nnn
n
n
n
aaa
aaa
aaa
aaa
A       (3.1) 
 
The matrix can be also be denoted as aij = 1/ aji ,, that is the matrix A is reciprocal. 
If at any level of hierarchy the attribute of Ci is of equal relative importance as Cj, then aij 
= 1, aji = 1; In particular aii = 1 for all i.  If our judgment is perfect in all comparisons then 
aik  = aij  * ajk  for all i,j,k, and we can call matrix A as a consistent matrix. In a consistent 
matrix the comparisons are based on exact measurements and; If the weights W1, to Wn 
are already known. Then 
aij   = 
j
i
w
w  (for i, j = 1, 2, …, n).     (3.2) 
thus 
aij  *  ajk =  
j
i
w
w  *
k
j
w
w  = 
k
i
w
w  = aik     (3.3) 
This leads to  
aji  = 
i
j
W
W  = 
 / Wji
1
w
 = 
 aij
1       (3.4) 
Considering the matrix equation  
A.x = y        (3.5) 
     
Where x = ( x1 , . . . . . . .xn ) and y = ( y1 , . . . . . . .yn ) 
i
n
1j
ij yxia =∑
=
, (for i = 1, 2, …, n).    (3.6) 
This gives us  
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aij * 
i
j
w
w  = 1, (for i, j = 1, 2, …,n).    
Consequently  
wi wja
n
1j
ij n=∑
=
(for i = 1, 2, …, n). 
Which is equivalent to 
Aw = n w        (3.7) 
where A is a consistent matrix. In general, small deviation in aij may lead to large 
deviations both in   Eigen value λmax and in iW  (for i = 1,2, to n).  It necessitates the need 
for stable solutions which satisfies the condition. The reciprocal matrix satisfies the 
conditions and gives a more stable solution. When considering the reciprocal of the 
matrix A which is represented as A', from the pair-wise comparisons, the solution can be 
represented as 
A'w' = n w'       (3.8) 
 Several approximation methods are available to identify the weights of the 
comparison vector of which, the most recommended method geometric approximation is 
utilized in this research. This method multiplies all the n elements in the pair-wise 
comparison matrix and the resulting weights of corresponding alternatives normal the 
results obtained by taking the nth root for matrix of n alternatives. 
From our example consider the priority vector matrix 
 
⎥⎥
⎥⎥
⎦
⎤
⎢⎢
⎢⎢
⎣
⎡
=
14/19/17/1
415/15/1
9513/1
7531
  A'  
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The multiplication of each row results in (105, 45/3, 4/25, and 1/252) 
respectively.  Each value is raised to the power 1/n.  In this example n = 4.  The result is 
represented by priority vector p  
⎥⎥
⎥⎥
⎥
⎦
⎤
⎢⎢
⎢⎢
⎢
⎣
⎡
=
)4/1(
)4/1(
)4/1(
)4/1(
252/1
25/4
3/45
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P  = 
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⎦
⎤
⎢⎢
⎢⎢
⎣
⎡
0.251 
0.632
968.1
3.201
 
 
These values are normalized using a linear normalization method.  The sum of the 
all elements of column vector P is calculated, each element is then divided by that sum of 
elements.  In our example, the sum of elements is found to be around 6.052. After 
normalization, the vector of weights is given by w. 
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⎢⎢
⎣
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=
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⎢
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3.5.3 Consistency Index and Consistency Ratio 
 Consistency of the decision is a big issue to be addressed in any decision making 
methodology. The matrix A (aij) is said to be consistent only if the principal eigen value 
λmax  is equal to or close to the order of the matrix (n). The sum of the eigen values of a 
matrix is equal to its trace which is also equal to n. 
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  The human involvement of AHP makes it difficult for any one to give the precise 
values of the pair-wise comparison ratio
j
i
w
w , rather only an estimate.  Therefore, Saaty 
replaces the equation Aw = nw with Aw = λmax w.  where λmax is the largest or principal 
eigen value of matrix A. Saaty defines the difference between λmax and n as a Consistency 
Index (CI).  
 
CI is calculated by 
1n
nλCI max−
−=       (3.9) 
 
The consistency index of randomly generated reciprocal matrix for the ratio scale 
1 to 9, with reciprocals forced is called as Random Index (RI). At Oak Ridge National 
Laboratory, Saaty generated an average random index (RI) for matrices of order 1-15 
using a sample size of 100. RI increases as the order of the matrix increases and is shown 
in the following table as the sample size was only 100 and statistical fluctuation of 
indexes from one order to the other (Table 3.2). 
 
Table 3.1 Average Random Index (Oakridge National Laboratory) 
N 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
RI 0.00 0.00 0.58 0.90 1.12 1.24 1.32 1.41 1.45 1.49 1.51 1.48 1.56 1.57 1.59 
 
The ratio of C.I to average R.I for matrix of the same order is defined as Consistency 
Ratio (C.R). 
C.R = C.I / R.I       (3.10) 
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Lower the consistency ratio will increase the consistency of the decision. Saaty 
recommends using matrices of consistency ratios less than 0.1. If the consistency ratio is 
greater than 0.1 such a matrix should be eliminated to calculate the weight so that the 
decision made is more rational. Thus AHP methods use a combination of C.R and 
powerful pair-wise comparison to resolve irrational humanistic responses. 
Ideally, aij =  
j
i
w
w  (for i, j = 1, 2, …, n). We use judgments which are quantified, 
and all the allowances must be integrated.  Deviations in the ratio aij and the number n, 
now denoted by λmax, leads to λmax 
∑
=
=
n
1j
jij
max
i wa
λ
1w   i = 1, 2, …, n     (3.11) 
A small deviation in aij can lead to a very large deviation in final weights. The 
consistency in decision should be maintained throughout for accurate measurement of the 
selection criteria. 
   
3.6 Synthesis of Priorities 
 Once we have obtained weights of criteria, the next step is to prioritize the 
alternatives based on the criteria. For each criterion the alternatives are prioritized based 
on the decision matrix and priorities are obtained. 
  Pair wise comparison of criterion color is shown as follows 
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⎥
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=   
 The matrix and the weights based on one of the criterion color as shown in the 
above equation. The weight is obtained via the method previously mentioned. Similarly 
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we can obtain the weights for other criteria including quality appearance and seediness 
(Table 3.3).  
 
Table 3.2 Weights Among Alternatives With Respect to Criteria 
Evaluation Color  Quality Appearance Seediness 
Weights 0.164798 0.185184 0.437111 0.212907 
Apple 0.230769 0.142857 0.177276 0.0704176 
Orange 0.076923 0.714286 0.0852256 0.751405 
Grapes 0.692308 0.142857 0.737498 0.178178 
 
3.7 Overall Priority for Final Selection 
 Finally, the priority weights of each alternative can be calculated by weights per 
alternative multiplied by weights of the corresponding criterion. The highest score of the 
decision matrix implies the best choice of fruit. Synthesizing the priorities will give us 
the weights of the criteria and the priorities of the alternatives based on each individual 
criterion. Now we have to obtain the overall priority ranks which will help us in making 
the decision. 
 For obtaining the overall ranking of alternatives we multiply the corresponding 
alternatives with the weights of the criterion weights. 
 Ranking = Priorities × Weights of Criteria    (3.12) 
The weight of alternative apple based on the criterion color is obtained by 
0.03803016472.0230769.0coloron  based apple ofWeight =×=  
Similarly weights of other alternatives are also obtained by sum product 
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Table 3.3 Sum Product of Matrix 
SUM  
PRODUCT Color  Quality Appearance Seediness Results 
Apple 0.03803 0.0264 0.0774892 0.014992 0.15696 
Orange 0.012676 0.1322 0.037253 0.159979 0.34218 
Grapes 0.11409 0.0264 0.3223684 0.037935 0.50084 
 
3.8 Results 
  According to the decision matrix final scores, grapes are the most preferred due to 
its high priority weight, Orange is the next recommended alternative. Through the 
illustration of this AHP model, it is found that the fruit selection problem can be solved in 
a structural and simple manner without involving much complexity. The sensitivity of 
each fruit with respect to the attributes and main criteria also can be obtained. The final 
priority weights of each fruit can be seen in Figure 3.3. The step by step computations 
and comparison matrices of all the attributes are shown. The important results are also 
shown in Figure 3.3. 
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Figure 3.3 Final Priority Weights Alternatives by Criterion 
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 The final priority weights of different criteria shows that the appearance of the 
fruit carries the highest priority and it is followed by seediness, quality and color, 
respectively. The factors that contribute most in fruit selection are appearance and 
seediness.  
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CHAPTER 4 
MODEL DEVELOPMENT 
 
4.1 Introduction 
This chapter discusses decision making involved in finding a trade-off between 
efficiency and equity outcomes which were modeled in a Multi-Criteria Decision 
Analysis framework using Analytic Hierarchy Process. Additionally, important decision 
criteria related to efficiency and equity involved in deciding the best policy are detailed. 
The criteria discussed include average MELD score, waiting time, racial and geographic 
equity which require considerable amounts of attention. We attempt to generalize the 
model for all organ transplantation including liver, kidney, and tissues etc.  
 
4.2 AHP Framework 
 Balancing efficiency and equity in U.S. liver transplantation can be modeled as a 
multi-criterion decision problem which includes both qualitative and quantitative factors. 
Reaching a consensus in selecting a policy is more complex when there are conflicting 
attributes involved. AHP based methodology will be discussed to tackle the different 
necessary but conflicting criteria. In our research criterion like efficiency and equity 
including the sub criterions involved in the selection of alternative policy based on 
existing liver transplantation scenario. In this research AHP is used to identify a 
consensus in which how much a system should be balanced in terms of efficiency and 
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equity outcomes. This research concentrates on a widely divided category of organ 
transplant’s outcomes; i.e. efficiency and equity.  The aim of the National Organ 
Transplant Act (NOTA) is to develop a policy which is efficient and equitable. 
Categorized outcomes are as shown in (Table 4.1). The table comprises some of the 
major outcomes which, we believe, affect an efficient and equitable distribution of 
harvested organs.   
 
Table 4.1 Classification of Efficiency and Equity Outcomes 
Efficiency Equity 
Average Cold Ischemic Time (Hours) Race 
No. of Previous Transplants Ethnicity Category 
Age in Years at Time Of Listing Gender 
Recipient Length of  Stay Post Transplant State of Residency  at Registration 
Recipient Died (1=Dead,0=Alive)  
Cold Ischemic Time (Hours)  
No. of Days on Liver Waiting List  
Average MELD Score  
Age In Years At Time Of Listing  
Recipient Length of  Stay From Transplant 
to Discharge  
Recipient Days Between Previous And 
Current Transplant  
Allocation Type: 
Local/Regional/National/Foreign  
 
We categorize the measurable outcomes into two main subsets: Efficiency and 
Equity. In the preliminary step for finding the optimal policy we break down the decision 
problem into further criteria. These criteria will aid in building the hierarchy model, thus 
facilitating the easy understanding of the problem and easing application of AHP 
methodology. 
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4.3 Selection Criteria for Liver Transplantation 
 Most decision makers cannot simultaneously handle more than 7 to 9 factors 
when making a decision involving alternatives that have multiple attributes. It is 
necessary to break down complex problems into more manageable sub problems which 
help decision making. There is a large number of contributing but conflicting factors 
simultaneously affecting the process of reaching a decision. An orderly sequence of steps 
should be required whereby a complex problem, is broken down into to sub-problems 
reducing complexity and produces an easy analysis. 
 Liver transplantation has four level of hierarchy.  The following sections discuss 
the different decision criteria, attributes and the decision alternatives. The objective is to 
select a best liver allocation policy which balances efficiency and equity for the U.S. liver 
transplantation system. Application of common criteria to all alternative policies makes 
pair-wise comparisons possible.  
The criteria which are considered are: 
 1. Efficiency 
 2. Equity 
 
4.4 Liver Transplantation Outcomes 
 Liver transplantation outcomes are divided into efficiency and equity outcomes.  
Our research focuses on efficiency and equity outcomes of the existing model for liver 
allocation. Efficiency refers to the utilitarian view towards the systems and intends to 
make the existing system efficiency oriented. In the equity oriented approach, the 
egalitarian view argues for the equity of the system in all terms including gender, race, 
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geography, etc. It is a challenge to develop a decision to process that is capable of 
balancing efficiency and equity amongst large number of alternatives.  
 
4.4.1 Efficiency Outcomes  
The efficiency criterion is an important criterion in assessing the policy because it 
can determine the effectiveness of the system in terms of utilization of scarce resources. 
A good policy cannot be possible without maximum utilization of the available 
transplantable livers. Considering a high rejection of more than 45%, maximum 
utilization of transplantable livers should have a major influence [57].  
While most of the medical factors including medical urgency, waiting time and 
age have been taken in consideration  some issues are not properly addressed; some of 
the major factors (attributes) affecting this criterion can be stated as follows 
 
4.4.1.1 Average MELD/ PELD Score 
 Efficiency of the system is attributed to the scoring model for calculating the 
severity of disease. The MELD score reflects the patient's risk of dying while waiting for 
a liver transplant based on clinical tests. . The MELD and PELD scores range from 6 to 
40 and are based on objective and verifiable medical data. The MELD score is used for 
adults, while the PELD score is used for patients who are less than 12 years of age. The 
higher the MELD or PELD score, the greater the risk of dying from liver disease 
The MELD score calculation uses: 
• Serum Creatinine (mg/dl)* 
• Bilirubin (mg/dl) 
• INR 
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MELD Formula 
 
MELD Score = 0.957 x Loge (creatinine mg/dL)  
 + 0.378 x Loge (bilirubin mg/dL)  
+ 1.120 x Loge (INR)  
+ 0.643  
Multiply the score by 10 and round to the nearest whole number. 
The PELD score calculation uses: 
• Albumin (g/dl) 
• Bilirubin (mg/dl) 
• INR 
• Growth failure (based on gender, height and weight) 
• Age at listing 
PELD Formula 
 
PELD Score = 0.480 x Loge (bilirubin mg/dL)  
+ 1.857 x Loge (INR) - 0.687 x Loge (albumin g/dL) 
+ 0.436 if patient is less than 1 year old  
+0.667 if the patient has growth failure 
Multiply the score by 10 and round to the nearest whole number. 
 
The likelihood of a critically ill person receiving a liver is higher than that of 
patient who has a higher recovery chance. In the current scoring system, the median wait 
time for re-transplant candidates is less than that of new transplant candidates. A 
factorization of the score can be done based on transplant history. One of the primary 
efficacy outcome is survival rate of patients after transplantation.  Additionally, the 
quality adjusted life years is another major outcome. Length of time in the waiting list 
and quality of the liver obtained also attribute a lot towards the efficiency issues. Average 
MELD score, length of hospitalization, rejection rate are secondary factors for deciding 
the efficiency of a transplant.  
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4.4.1.2 Average Waiting Time 
The length of time spent on the waiting list is another major attribute for the 
efficiency of the system. For a more efficient system it is necessary that the average wait 
time be reduced. This is a major factor in the measuring MELD scores. The wait time 
determines the priority when there is a tie amongst patients of similar MELD or PELD 
scores. 
4.4.1.3 Acceptance Rate 
Higher acceptance rate is directly related to the efficiency of the policy. It is 
necessary for any alternative policy to have a very low rejection rate. There is a wide gap 
between the available livers for transplantation and number of patients in the waiting list. 
Liver transplantation is very expensive and costs hundreds of thousands of dollars. A 
higher acceptance rate can substantiate the high cost involved with liver transplantation 
and associated costlier post transplant medication. 
4.4.2 Equity Outcomes  
 Equity of the liver allocation system should be viewed as equal as efficiency. The 
measurement of equity contributes toward the fairness of a policy. Numerous criteria 
which we can measure equity; are blood group, race, insurance, health conditions, 
ethnicity, transplant OPO etc, as such important for any policy to be fair so that no policy 
should be biased on things beyond their control. Our research considers, what we think, a 
major contribution toward the equitable allocation via as geography, race and gender. We 
consider the measurements as we view their inclusion as a means to create a more 
equitable policy. Equity outcomes in this research are measured in terms of the difference 
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in scores of specific efficiency outcomes over patient. For example The difference in the 
MELD score across Hispanics Asians, Whites and African Americans. 
 
4.4.2.1 Geographical Equity 
Geographical equity is one of the major contributions toward the fairness of liver 
allocation policies. The regional variability in wait time has prompted vigorous debate on 
organ allocation policy. Certain parts of the nation failed to benefit from the regional bias 
of current liver allocation policy. It is necessary for an ideal policy to reduce the regional 
variability in allocation of livers. 
 
4.4.2.2 Gender Equity 
There is a wide disparity in the post transplant survival rate and acceptability of 
organs based on the male and female. Any ideal policy should be able to recognize and 
reduce this disparity to its bare minimum while maintaining an acceptable efficiency 
level.  
 
4.4.2.3 Racial Equity 
Another major equity criterion measured is race. No policy should disadvantage 
anyone for belonging to a certain race. Even though the current system does not explicitly 
account for racial consideration, it is observed that there is a high racial disparity in the 
number of transplants as well as the waiting time for people belonging to a particular 
race. Any system should be fair in such a way that the difference among the race in terms 
of efficiency attributes should be minimized or negligible. 
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 For all the major equity criteria and corresponding sub criteria, pair wise 
comparisons are done in terms of the difference in the efficiency attributes. For example 
if we consider the geographical equity criterion we will measure the difference in average 
wait time across the different regions based on the national average. Similarly pair wise 
comparison will be done for other criteria to obtain a quantitative justification in 
determining priorities among the criteria. 
 
4.5 Hierarchy Model 
 
Figure 4.1 Evolution of AHP Model for Balancing Efficiency and Equity 
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4.6 Discussion of Methodology and Application 
The problem discussed is the U.S. Liver transplantation and allocation policy; 
searching for the best policy for balancing efficiency and equity. The research takes into 
account the majority of possible criteria which can affect the decision maker. A detailed 
discussion on every criterion, sub criterions, attributes and alternative policy has been 
presented. Two critical criteria have been identified. The methodology has been used 
further to select the numerous attributes (or sub-criteria) with for evaluating among 
alternative policies. 
The following steps have been considered to form the hierarchy: 
(1) Define the issues considering the U.S. liver transplantation. 
(2) Identify the overall objective of policy selection. 
(3) Identify the criteria and attributes that must be satisfied to fulfill the overall 
objectives. 
(4) Identify decision alternatives or outcomes. 
(5) Structure the hierarchy placing the objective at first level, criteria at second 
level, attributes at third level, and decision alternatives at fourth level. 
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CHAPTER 5 
DATA ANALYSIS AND RESULTS 
 
5.1 Introduction 
In this chapter we will discuss about the sources of data, data extraction methods, 
variables for analysis, simulation models, and data analysis software. 
 
5.2 UNOS Data  
 The UNOS operates the national system for organ transplantation. As mandated 
by policy, all transplanting institutions must report certain information for each transplant 
performed. The UNOS liver committee selects the relevant set of variables to be report, 
which are collected on standardized forms made available by UNOS. UNOS makes the 
information publicly available in electronic format.  
  Two sets of latest data requested from UNOS.  
1. Patient registration data 
2. Patient follow-up data 
 
5.2.1 Patient Registration Data 
This data is provided as a SAS cport file. A cport file is a sequential file 
containing one or more data sets or catalogs in SAS format. "Transport format" is a 
format understood by all versions of SAS in all systems. The data contains waiting list / 
transplant files. UNOS Standard Transplant Analysis and Research (STAR) files for liver 
registrations and transplants were obtained. The transplant STAR file from UNOS 
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contains information on all waiting list registrations and transplants of livers that have 
been listed or performed in the U.S. and reported to the OPTN since October 1, 1987. 
The data includes both deceased and living-donor transplants. There is one record per 
waiting list registration/transplant event. Each record includes the most recent follow-up 
information (including patient and graft survival) reported to the OPTN as of June 2006. 
The patient information dataset consists of 142,873 records and 418 variables. These 
variables are further classified into post transplant clinical information, pre-transplant 
clinical Information, candidate information, donor information, waiting list data, etc. 
 
5.2.2 Patient Follow-Up Data 
The follow-up STAR file contains one record for each pre-transplant 
measurement. There are multiple records per transplant for most cases. For instance, if a 
patient was transplanted in January 1998, the graft has not failed, and the patient has not 
been reported lost to follow-up database, we have many follow-up records with the same 
transplant identification number i.e. transplant id. Follow up records for 6 month, 1 year, 
2 year, 3 year, 4 year, 5 year, and 6 year etc can be obtained for each patient.  The 
variable for linking the follow-up data to the transplant STAR file is TRR_ID.  The 
number of record of patient ranges from one record to more than hundred records per 
patient based on number of visits or tests conducted. The patient follow up dataset 
consists of 675,279 records and 20 variables. Most of the variables are from the waiting 
list category.  
5.3 Statistical Analysis System (SAS) 
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The SAS system is an integrated system of software products provided by the 
SAS Institute that enables programmers to perform data analysis. In this research latest 
version of SAS 9.1.3 (released on April 2006) licensed to University of South Florida is 
used. 
 
5.4 Data Patterns and Simulation Model 
 The main objectives of data analysis are to understand the system and to obtain 
the inputs for a discrete-event liver transplantation simulation model. The simulation 
model is intended to replicate the real life system. Patient’s cumulative distribution can 
be obtained by using their MELD scores as input from the patient registration dataset. 
This data was extracted from corresponding SAS dataset by avoiding the duplicates and 
based on the year of focus. Appendix A presents the sas program to determine the 
variables for extraction and the procedure for extracting the data. The different outcome 
categories and configurations based the data input comprise the input for the simulation 
model that will be described later in the chapter. 
  
5.5 Extraction Procedures and SAS Data Sets 
The SAS software package was used to extract the data from the database. SAS 
file Extract1.sas is presented in Appendix A and was used as the master program that aids 
in identifying the variables needed from each data file. These variables will be described 
in more detail in the next section. Figure 5.1 illustrates the complete procedure used in 
extracting all data in tables.  
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Figure 5.1 SAS Data Extraction Flow Chart 
 
The hexagonal blocks represents the processing steps, the square blocks represent 
the data sets and tabulated results. The purpose of the PROC (Procedural) step is to 
perform operations on data obtained from data step. Finally, the results of the analysis 
were processed using Excel.  
 The analyzed data serve as input to the simulation model. The simulation model is 
a clinically based, discrete event simulation model of ESLD in the United States. The 
model is used for policy evaluation. It used input clinical data obtained from the analysis. 
The model is used to generate outcomes. The outcomes are evaluated based on expert’s 
opinion to obtain the weights of the evaluation criteria. Impacts on changes in policy to 
various outcomes can be measured in this model. 
  
5.5.1 Organ Procurement Organizations (OPO) 
 Each OPO considered is classified either as a transplant OPO or a donor OPO 
depending on its functionality. For this research it is necessary to fix the number of 
transplant and donor OPOs. We obtained all the distinct OPOs in use at any given time 
starting from its inception. We are able to identify 87 donor OPOs and 57 transplant 
OPOs. These are the variables that we obtained from the dataset: 
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CTR_OPO --Transplant OPO.  
OPO_CTR -- Donor OPO. 
  The dataset obtained is displayed in appendix B. 
 
5.5.2 Regions and Transplant OPOs  
 The entire UNOS is divided into 11 regions for geographical allocation and 
administrative purposes. Each OPO belongs to certain region based on the proximity. 
Each region consists of multiple OPOs. It is necessary to find the regional allocation of 
OPOs for all the identified transplant and donor OPOs. This information will be used to 
evaluate regional equity. We classified the two major categories of OPOs to their 
respectable regions. 
 Variables used from the dataset 
 Region – Region which an OPO belongs to. 
CTR_OPO --Transplant OPO. 
OPO_CTR -- Donor OPO. 
 We are able to classify all OPOs into different regions based on the analysis and 
the result will be obtained from appendix C. 
 
5.5.3 Discrete Distributions 
  This analysis provides the patient arrival rate for the simulation model. We fixed 
the number of transplant OPOs as 57 for the research purpose. For 142,873 patient’s 
information which we obtained the patients transplant OPOs, a discrete distribution based 
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on these OPOs was obtained. There is wide disparity in the number of transplants. 
Patients from New York and California nearly attributes to the 15% of all the transplants. 
 
5.5.4 Cold Ischemic Time 
 Cold Ischemic time is a major factor that determines the quality of transplant livers. 
Preservation methods are available for storing livers without much deterioration in 
quality for at least 12 hours [58]. We conducted this analysis by finding the distance 
between the Donor and Transplant OPOs and the cold ischemic time of patients for that 
transplant. We sorted the entire database based on the distance between the transplant 
center and the mean cold ischemic time is extracted. Few transplants have taken place 
when the donor and transplant OPOs are more than 2500 miles. For close analysis the 
OPOs are further subdivided to the distance of 100 miles for distance less than 2500 
miles. For distance less than 500 miles we further divided the distance into sub categories 
of 50 miles. A normal distribution was fitted with 95% confidence interval. 
 
 
5.6 Data Variables and Hierarchy 
A hierarchy model helps decompose the problem in several stages. The aim of the 
model is to obtain a policy among the alternative policy recommendations. How do we 
test the alternative policies? Alternative policies can be tested for efficiency and equity 
based on certain outcomes of the policy that are obtained from the simulation model. 
The model generates waiting list times and survival rates, graft failure, and re-
transplant rates under the current UNOS liver allocation strategy, which emphasizes the 
severity of disease and incorporates the MELD risk score. A set of outcomes for various 
policies being obtained from the simulation model. 
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The outcomes of the simulation model were reviewed by experts. These Experts 
include transplant policy makers, physicians, and or focus groups among patients. They 
suggest the importance of the outcomes. Values from the outcomes obtained from the 
survey can be used to calculate the weights. This will help prioritize the impact of 
allocation policy and the contribution of each policy towards efficiency and equity of the 
model. 
 
5.7 Merge – Registration and Follow-Up Data 
The main objective of this part of the analysis is to create a library to store the 
extracted data and create a working data set from each of the two distinct data sets. As 
mentioned above, the database includes two datasets files, the patient registration data 
and patient follow-up dataset, necessary variables from each file were chosen from the 
data sets and finally the files were merged by patient id number (wl_id in the database). 
Merging was done to obtain the patient file information where the necessary variables for 
analysis were found in two different datasets 
The Extract1.sas was updated in every analysis. Specific data sets are extracted 
from the database based on certain parameters for example based on year, MELD score, 
PELD score etc. In order to extract a specific set of data in a tabular format, smaller SAS 
programs were created. Sample sas program (Subextract.sas) is presented in Appendix A. 
This program extracts the patient id, initial and final MELD scores, Dates of visit to 
transplant center etc from the follow up file. 
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CHAPTER 6 
CONCLUSIONS AND FUTURE WORK 
 
6.1 Concluding Remarks 
  In this research we studied efficiency and equity, two major conflicting factors of 
the United States liver transplantation. This research aims to find a policy which balances 
efficiency and equity of current liver transplantation. The problem was modeled using 
Analytic Hierarchy Process.  
This research classifies the outcomes of liver transplantation into two major 
criteria: efficiency and equity. The majority of the attributes contributing towards these 
criteria have been identified. Some of the attributes which contribute to efficiency are 
average MELD score, length of wait time, and patient rankings. Major attributes that 
contributed toward equity included geographical location, race and gender. The AHP 
approach helps quantify the decision making process to build logics into a complex 
decision evaluation process that involves policy selection. The proposed model is capable 
of obtaining the weights of these defined attributes with the goal of establishing the major 
criteria regarding efficiency and equity.  
Results from our data analysis that used the latest UNOS data, serve as inputs for 
a simulation model. The simulation model is capable of evaluating different strategies for 
liver allocation; the resulting outcomes can be quantified for decision making purposed 
using the proposed model. The AHP methodology helps decision makers reach a 
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consensus in a quantifiable method whereas previous methods heavily rely on intuition. 
 This research studies the deficiencies of the current liver transplantation policy 
and proposes alternative strategies that may help policy makers search for a better policy 
to balance efficiency and equity. Measurement of alternative policies can be done using 
the simulation model. The proposed model is flexible enough to accept future changes in 
the U.S. liver transplantation policy. 
 
6.2 Future Extensions 
Some of the extensions that can be made for this research are: 
1. Selection of proposed policy can be done through AHP model. 
2. Different perspectives (policy makers or patients) towards the allocation 
policies can be studied. 
3. The optimality criterion can be included for future research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 50
 
 
REFERENCES 
 [1] Kenneth D. Kochanek, M.A., and Betty L. Smith, B.S. Ed. Deaths: Preliminary data 
for 2002. National vital statistics reports; Volume 52 Issue 13, Division of Vital 
Statistics. 2004. 
 
[2]  UC Atlas of Global Inequality available from http://ucatlas.ucsc.edu/spend.php 
accessed on October 2 2006. 
 
[3]  OECD Health Data 2005: How Does the United States Compare 
www.oecd.org/health/healthdata accessed on October 2 2006. 
 
[4]  Center for Medicare and Medicaid Services, 2006. Available from 
http://cms.hhs.gov/ information and data accessed on October 2, 2006. 
 
[5]  National Health Care Expenditures Projections: 2005-2015 February 22 2005 
available from http://www.openminds.com/indres/CMSprojections2006.htm 
information and data accessed on October 2, 2006. 
 
[6]  World Health Report 2000. Available at: http://www.who.int/whr/2001/ 
 archives/2000/en/index.htm. Accessed October 2, 2006. 
 
[7]  Borger, C Health Spending Projections Through 2015: Changes on the Horizon, 
Health Affairs Web Exclusive W61: 22 February 2006. 
 
[8]  California Health Care Foundation. Health Care Costs 101 -- 2005. 02 March 2005. 
 
[9]  Business communication company Inc., 25 Van Zant Street, Norwalk, CT 06855 
available from http://bccresearch.com/editors/RB-103R.html Accessed August 13, 
2006. 
 
[10] The official U.S. Government web site for organ and tissue donation and 
transplantation, www.organdonor.gov, Accessed August 13, 2006. 
 
[11] National Kidney Foundation. 25 Facts about Organ Donation and Transplantation 
  http://www.kidney.org/news/newsroom/fsitem.cfm?id=30 Accessed August 13, 
2006. 
 
[12]  IOM. Organ Procurement and Transplantation. National Academy Press, 
Washington, D. C., 1999. Available from Institute of Medicine (IOM) website, 
http://www.iom.edu/. 
 
 51
[13] Organ procurement and transplantation network. www.optn.org Data 2000 – 2001. 
 
[14] UNOS, 2006. Available from http://www.unos.org, information and data accessed 
on August 16, 2006. 
 
[15] Organ procurement and transplantation network [Internet]. Richmond (VA): United 
Network for Organ Sharing; c2003 [modified 2005 Nov 18; cited 2005 Nov 23]. 
Available from: http:// www.optn.org/latestData/step2.asp?. 
 
[16] Gilbert JR, Pascual M, Schoenfeld DA, et al. Evolving trends in liver 
transplantation: an outcome and charge analysis. Transplantation. 1999;67(2):246-
53. 
 
[17] Belle SH, Beringer KC, Detre KM. An update on liver transplantation in the United 
States: recipient characteristics and outcome. In: Terasaki CA, ed. Clinical 
transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1995:19-33. 
 
[18]  Klassen AC, Klassen DK, Brookmeyer R, Frank RG, Marconi K. Factors 
influencing waiting time and successful receipt of cadaveric liver transplant in the 
United States, 1990 to 1992. Med Care 1998;36:281-294. 
 
[19] Furukawa H, Todo S, Imventarza O, et al. Effect of cold ischemia time on the early 
outcome of human hepatic allografts preserved with UW solution. Transplantation 
1991;51:1000-1004. 
 
[20] Padbury RT, Attard A, Mirza DF, et al. Extended preservation of the liver with UW 
solution -- is it justifiable? Transplantation 1994;27:1490-1493. 
 
[21] P. A. Ubel and A. L. Caplan. Geographic favoritism in liver transplantation– 
 unfortunate or unfair? New England Journal of Medicine, 339(18):1322–1325, 1998. 
 
[22] Siminoff LA, Arnold RM, Caplan AL, Virnig BA, Seltzer DL. Public policy 
governing organ and tissue procurement in the United States: results from the 
National Organ and Tissue Procurement Study. Ann Intern Med 1995;123:10-17. 
 
[22] National Organ Transplant Act: Public Law 98-507.U.S. Statut Large.1984;98:2339 
48. 
 
[23] Steward A. Jersey lawmakers vow to fight changes in organ transplant rules. The 
Star Ledger. May 5, 1998:28. 
 
[24] Government Accounting Office, 2003. Available from http://www.gao.gov/ special. 
pubs/organ/chapter2.pdf, information and data accessed on January 21, 2003. 
 
[25] Saaty, Thomas L. (1980). The Analytic Hierarchy Process: Planning, Priority 
Setting, Resource Allocation. McGraw-Hill. New York. 
 52
[26] Vaidya, O. S., and Kumar, S., 2006, “Analytic hierarchy process: an overview of 
applications” European Journal of Operational Research, 169, 1-29.  
 
[27] Triantaphyllou, Evangelos (2000). Multi-criteria Decision Making Methods: A 
Comparative Study. Kluwer Academic Publishers. Boston.   
 
[28] Ernest H. Forman; Saul I. Gass The Analytic Hierarchy Process: An Exposition (in 
OR Chronicle) Operations Research, Vol. 49, No. 4. (Jul. - Aug., 2001), pp. 469-
486.  
 
[29] J. A. Sharp Haulier Selection-An Application of the Analytic Hierarchy Process (in 
Case-Oriented Papers) The Journal of the Operational Research Society, Vol. 38, 
No. 4. (Apr., 1987), pp. 319-328.  
 
[30] R.F. Dyer and E.H. Forman, Group decision support with AHP, Decision Support 
Systems 8 (1992) (2), pp. 99–124.  
 
[31] S.L. Ahire and D.S. Rana, Selection of TQM pilot projects using an MCDM 
approach, International Journal of Quality & Reliability Management 12 (1995) (1), 
pp. 61–81. 
 
[32] Kyung S Park and Chee Hwan Lim A structured methodology for comparative 
evaluation of user interface designs using usability criteria and 
measures International Journal of Industrial Ergonomics, Volume 23, Issues 5-6, 20 
March 1999, Pages 379-389. 
 
[33] D.R. Cook et al., Equitable allocation of levers for orthotopic transplantation: An 
application of AHP, European Journal of Operational Research 48 (1990) (1), pp. 
49–56. 
 
[34] S. Hariharan, P.K. Dey and D.R. Chen et al., Application of analytic hierarchy 
process for measuring and comparing the global performance of intensive care units, 
J Crit Care 20 (2005), pp. 117–124. 
 
[35]Cheng-Ru Wu, Chin-Tsai Lin and Huang-Chu Chen Optimal selection of location for 
Taiwanese hospitals to ensure a competitive advantage by using the analytic 
hierarchy process and sensitivity analysis. 
 
[36] M.D. Rossetti and F. Selandari, Multi-objective analysis of hospital delivery 
systems, Computers and Industrial Engineering 41 (2001) (3), pp. 309–333. 
 
[37] Hokey Min, Amitava Mitra and Sharon Oswald , Competitive benchmarking of 
health care quality using the analytic hierarchy process: an example from Korean 
cancer Clinics Socio-Economic Planning Sciences, Volume 31, Issue 2, June 1997, 
Pages 147-159. 
 53
[38] N. Singpurwalla, E. Forman and D. Zalkind, Promoting shared health care decision 
making using the analytic hierarchy process, Socio-Economic Planning Sciences 33 
(1999) (4), pp. 277–299 
 
[39] Matthew J. Liberatore, Ronald E. Myers, Robert L. Nydick, Michael Steinberg, Earl 
R. Brown, Roy Gay, Thomas Powell and Roberta Lee Powell, Decision counseling 
for men considering prostate cancer screening  Computers & Operations Research, 
Volume 30, Issue 10, September 2003, Pages 1421-1434. 
 
[40] Dolan, J. G., 1989, “Medical decision making using the analytic hierarchy process: 
choice of initial antimicrobial therapy for acute pyelonephritis” Medical Decision 
Making, 9 (1), 51-56. 
 
[41] Dolan, J. G., 1995, “Are patients capable of using the analytic hierarchy process and 
willing to use it to make clinical decisions?” Medical Decision Making, 15 (1), 76-
80. 
 
[42] Dolan, J. G., and Bordley, D. R., 1993, “Involving patients in complex decision 
about their care: an approach using analytic hierarchy process” Journal of General 
Internal Medicine, 8 (4), 204-209. 
 
[43] Franco Sassi Setting priorities for the evaluation of health interventions: when theory 
does not meet practice  Health Policy, Volume 63, Issue 2, February 2003, Pages 
141-154. 
  
[44] Elliot B. Sloane, Matthew J. Liberatore, Robert L. Nydick, Wenhong Luo and Q. B. 
Chung Using the analytic hierarchy process as a clinical engineering tool to facilitate 
an iterative, multidisciplinary, microeconomic health technology assessment  
Computers & Operations Research, Volume 30, Issue 10, September 2003, Pages 
1447-1465 Elliot B. Sloane, Matthew J. Liberatore, Robert L. Nydick, Wenhong Luo 
and Q. B. Chung. 
 
[45] K. L. Poh and B. W. Ang Transportation fuels and policy for Singapore: an AHP 
planning approach Computers & Industrial Engineering, Volume 37, Issue 3, 1 
November 1999, Pages 507-525. 
 
[46] Yongyuan Yin and Stewart J Cohen Identifying regional goals and policy concerns 
associated with global climate change  Global Environmental Change, Volume 4, 
Issue 3, September 1994, Pages 245-260. 
 
 [47] Annual report of the U.S. Scientific Registry of Transplant Recipients and the 
Organ Procurement and Transplantation Network — transplant data: 1988–1994. 
Richmond, Va.: United Network for Organ Sharing, 1995. 
 
[48] Richard B. Freeman Jr, MD 1 *, Russell H. Wiesner 2, Ann Harper 3, Sue V. 
McDiarmid 4, Jack Lake 5, Erick Edwards 3, Robert Merion 6 7, Robert Wolfe 8 9, 
 54
Jeremiah Turcotte 6, Lewis Teperman 2, Liver Transplantation Volume 8, Issue 9 , 
Pages 851 – 858. 
 
[49] Tom Koch  The Art of Science National transplant system: What's fair and what's 
possible? OR/MS Today - October 2001. 
 
[50] Koch, T., "Organ transplants without borders," National Post, (April 2001) pgs. A 
13, 30. 
 
[51] Koch, T., "The Limits of Principle: Deciding Who Lives and What Dies," Westport, 
Conn.: Praeger Publishing, 1998 
 
[52] Weber, E. H. (1978). The sense of touch. Academic Press for Experimental 
Psychology Society. New York. 
 
[53] Fechner, G. (1966). Elements of Psychophysics. Translated by Helmut E. Adler, 
Holt, Rinehart, and Winston. New York. 
 
[54] Saaty, Thomas L. and Vargas, Luis G. (2001). Models, Methods, Concepts and 
Applications of the Analytic Hierarchy Process. Kluwer Academic Publishers. 
Boston.   
 
[55] Miller, G. A. (1956). The magical number seven plus or minus two: some limits on 
out capacity for processing information. Psychological Rev. 63 81-97. 
 
[56] Felix T.S. Chan and Niraj Kumar Global supplier development considering risk 
factors using fuzzy extended AHP-based approach  Omega, Volume 35, Issue 4, 
August 2007, Pages 417-431. 
 
[57] Howard, D. H. (2002). Why do transplant surgeons turn down organs?: A model of 
the accept/reject decision, Journal of Health Economics 21(6): 957{969). 
 
[58] Southard JH, Belzer FO. Organ preservation. Annu Rev Med 1995;46:235-247. 
 
 
 
 
 
 
 
 
 
 
 
 
 55
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 56
Appendix A: Statistical Analytics Systems Program 
/* Initializing the CPORT File and Data Extraction*/ 
libname lib "C:\Documents and Settings\vveerach\Desktop\SAS\newdata";   
/* where you want the new data to go */ 
Filename tranfile 'C:\Documents and 
Settings\vveerach\Desktop\newdata\LIVER_PUBLIC_USE_WLHIST_CPORT_FILE';  
/* Where the transport file is stored now */ 
 
 proc cimport library=lib infile=tranfile; 
run; 
 
options fmtsearch = (newlib)  /* this will enable SAS to find the 
formats in the catalog*/ 
libname lib "C:\Documents and Settings\vveerach\Desktop\SAS\newdata";  
 
/*Extracting the value coloumns from the table*/ 
proc sql; 
create table anew as select x.WL_ID, 
  x.ASCITES_DATE, 
  x.MELD_PELD_LAB_SCORE 
from lib.Liver_wlhistory_data x; 
run; 
 
proc sql; 
create table meldnew as select distinct WL_ID,Date, 
meld_peld_lab_score, MELD_OR_PELD 
from Anew 
where meld_peld_lab_score and date is not missing; 
group by wl_id; 
run; 
 
  
proc sort data=Anew; 
  by WL_ID ASCITES_DATE; 
run; 
  
data meld_prog_date; 
    set Anew; 
    by wl_id; 
    retain dt -1; 
    if first.wl_id then do; 
          days=0; 
          dt =ASCITES_DATE ; 
    end; 
    else do; 
         days = ASCITES_DATE - dt; 
    end; 
    drop dt; 
   where wl_id and ascites_date is not missing and meld_or_peld = 
'MELD'; 
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Appendix A: (Continued) 
drop meld_or_peld; 
run; 
proc print; run; 
 
 
proc sort data=meld_prog_date out=meld_prog_date_norepli nodupkey; 
by wl_id ascites_date; 
run; 
 
data MELD_Progression; 
set d3; 
drop ASCITES_DATE; 
drop meld_or_peld; 
run; 
 
 
 
proc freq data=d3; 
by wl_id; 
run; 
 
 
/*New Programs*/ 
 
data newtab; 
    set Anew; 
    by wl_id; 
    do; 
         days = ASCITES_DATE - MDY(01,01,1999); 
    end; 
    drop dt; 
   where wl_id and ascites_date is not missing; 
run; 
proc print; run; 
 
data newtab_final; 
set newtab; 
where days >=0 and _SCORE>=6; 
run; 
 
proc sort data=newtab_final out=result2 nodupkey; 
by wl_id ascites_date; 
run; 
 
proc contents data=a.a; 
run; 
 
 
proc sql; 
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Appendix A: (Continued) 
create table result3 as select WL_ID, Days, meld_peld_lab_score 
from result2; 
run; 
 
 
/*Remove Missing*/ 
 
proc sql; 
create table newtable as select distinct WL_ID,ASCITES_DATE, 
MELD_PELD_LAB_SCORE 
from Anew 
where ASCITES_DATE and MELD_PELD_LAB_SCORE is not missing; 
run; 
 
data newtable1; 
set newtable; 
where ascites_date le mdy(1,1,2003); 
run; 
 
 
/*No Missing*/ 
proc sort data=newtable1 out=Followup_2003; 
by descending ascites_date; 
run; 
 
proc sort data=followup_2003 nodupkey; 
by wl_id; 
run; 
 
 
proc sql; 
create table new as select distinct WL_ID,ASCITES_DATE, 
MELD_PELD_LAB_SCORE 
from Anew 
where ASCITES_DATE and MELD_PELD_LAB_SCORE is not missing; 
run; 
 
data new1; 
set new; 
where ascites_date le mdy(1,1,2002); 
run; 
 
 
/*No Missing*/ 
proc sort data=new1 out=Followup_2002; 
by descending ascites_date; 
run; 
 
proc sort data=followup_2002 nodupkey; 
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Appendix A: (Continued) 
by wl_id; 
run; 
 
/*Coverting days from January 2002 to number of days*/ 
data newtab; 
    set followup_2002; 
    do; 
         days = ASCITES_DATE - MDY(01,01,2002); 
    end; 
run; 
 
proc sql; 
create table finalfinal as select WL_ID, Days, meld_peld_lab_score 
from newtab; 
run; 
/*Start New 2002 2003 2004 2005 */ 
data new1; 
set new; 
where ascites_date le mdy(1,1,2003); 
run; 
 
 
/*No Missing*/ 
proc sort data=new1 out=Followup_2003; 
by descending ascites_date; 
run; 
 
proc sort data=followup_2003 nodupkey; 
by wl_id; 
run; 
 
 
data newtab2003; 
    set followup_2003; 
    do; 
         days = ASCITES_DATE - MDY(01,01,2002); 
    end; 
run; 
 
proc sql; 
create table final_followup_2003 as select WL_ID, Days, 
meld_peld_lab_score 
from newtab2003; 
run; 
 
 
data new1; 
set new; 
where ascites_date le mdy(1,1,2004); 
run; 
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Appendix A: (Continued) 
/*Sorting and Ascending by removing the duplicates Missing*/ 
proc sort data=new1 out=Followup_2004; 
by descending ascites_date; 
run; 
 
proc sort data=followup_2004 nodupkey; 
by wl_id; 
run; 
 
 
data newtab2004; 
    set followup_2004; 
    do; 
         days = ASCITES_DATE - MDY(01,01,2002); 
    end; 
run; 
 
proc sql; 
create table final_followup_2004 as select WL_ID, Days, 
meld_peld_lab_score 
from newtab2004; 
run; 
 
 
 
data new1; 
set new; 
where ascites_date le mdy(1,1,2005); 
run; 
 
 
/*No Missing*/ 
proc sort data=new1 out=Followup_2005; 
by descending ascites_date; 
run; 
 
proc sort data=followup_2005 nodupkey; 
by wl_id; 
run; 
 
 
data newtab2005; 
    set followup_2005; 
    do; 
         days = ASCITES_DATE - MDY(01,01,2002); 
    end; 
run; 
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Appendix A: (Continued) 
proc sql; 
create table final_followup_2005 as select WL_ID, Days, 
meld_peld_lab_score 
from newtab2005; 
run; 
 
 
/*Meld And PELD SCORE*/ 
data End2002; 
set Final_followup_2002; 
where MELD_PELD_LAB_SCORE>=6; 
run; 
 
 
data End2003; 
set Final_followup_2003; 
where MELD_PELD_LAB_SCORE>=6; 
run; 
data End2004; 
set Final_followup_2004; 
where MELD_PELD_LAB_SCORE>=6; 
run; 
 
data End2005; 
set Final_followup_2005; 
where MELD_PELD_LAB_SCORE>=6; 
run; 
 
 
/*CHANGE IN MONDAY*/ 
Data FINAL_FOLLOW_UP; 
    set followup_all; 
    by wl_id; 
    do; 
         days = ASCITES_DATE - MDY(01,01,2002); 
    end; 
    drop dt; 
   where wl_id and ascites_date is not missing; 
   retain ascites_date; 
run; 
 
proc sql; 
create table final_all_all as select WL_ID, Days, meld_peld_lab_score 
from final_follow_up; 
run; 
 
data final_all; 
set final_all_all; 
where days >0; 
run; 
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Appendix A: (Continued) 
proc sort data=final_all nodupkey; 
by wl_id days; 
run; 
 
 
PROC SORT DATA=a.Final_2003; 
BY wl_id; 
PROC SORT DATA=a.Final_followup_2003; 
BY wl_id; 
DATA widedata; 
MERGE a.final_2003 a.Final_followup_2003; 
BY wl_id; 
RUN; 
 
/*Merging the data sets from Patient Registration and patient follow up 
database*/ 
data three; 
      merge a.Final_2003(in=fromdadx) 
a.Final_followup_2003(in=fromfamx);  
      by wl_id;   
     
     fromdad = fromdadx; 
    fromfam = fromfamx;         
   if fromdad=1 and fromfam=1; 
     run; 
PROC FREQ DATA=three; 
TABLES fromdad*fromfam; 
where fromdad=1 and fromfam=1; 
RUN;  
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Appendix B: Donor and Transplant OPO 
Table B.1 Transplant OPO vs. Donor OPO 
No Transplant OPO Donor OPO 
1 ALOB-OP1  ALOB-OP1 
2 AROR-OP1 11 AROR-OP1 
3 AZOB-OP1  AZOB-OP1 
4 CADN-OP1  CADN-OP1 
5 CAGS-OP1  CAGS-OP1 
6 CAOP-OP1  CAOP-OP1 
7 CARO-OP1  CARO-OP1 
8 CASD-IO1  CASD-IO1 
9 CORS-OP1  CORS-OP1 
10 CTOP-OP1  CTOP-OP1 
11 DCTC-OP1  DCTC-OP1 
12 FLMP-OP1  FLFH-IO1 
13 FLUF-IO1  FLMP-OP1 
14 FLWC-OP1  FLSW-OP1 
15 GALL-OP1  FLUF-IO1 
16 HIOP-OP1  FLWC-OP1 
17 IAOP-OP1  GALL-OP1 
18 ILIP-OP1  GAMC-IO1 
19 INOP-OP1  HIOP-OP1 
20 KYDA-OP1  IAIV-IO1 
21 LAOP-OP1  IAOP-OP1 
22 MAOB-OP1  ILCL-OP1 
23 MDPC-OP1  ILCR-OP1 
24 MIOP-OP1  ILIP-OP1 
25 MNOP-OP1  INOP-OP1 
26 MOMA-OP1  KYDA-OP1 
27 MSOP-OP1  LAOC-OP1 
28 MWOB-OP1  LAOP-OP1 
29 NCCM-IO1  LAOS-OP1 
30 NCNC-OP1  LASU-IO1 
31 NEOR-OP1  MAOB-OP1 
32 NJTO-OP1  MDPC-OP1 
33 NMOP-OP1  MIOP-OP1 
34 NYFL-IO1  MNOP-OP1 
35 NYRT-OP1  MNRC-OP1 
36 OHLB-OP1  MOMA-OP1 
37 OHLC-OP1 12 MSOP-OP1 
38 OHLP-OP1  MWOB-OP1 
39 OHOV-OP1  NCBG-IO1 
40 OKOP-OP1  NCCM-IO1 
41 ORUO-IO1  NCNC-OP1 
42 PADV-OP1  NEOR-OP1 
43 PATF-OP1  NJTO-OP1 
44 SCOP-OP1  NMOP-OP1 
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Appendix B: Donor and Transplant OPO 
Table B.1 (Continued) 
No Transplant OPO Donor OPO 
45 TNDS-OP1  NVLV-OP1 
46 TNMS-OP1  NYAP-OP1 
47 TXGC-OP1  NYFL-IO1 
48 TXSA-OP1  NYRC-OP1 
49 TXSB-OP1  NYRT-OP1 
50 UTOP-OP1  NYSB-IO1 
52 VAOP-OP1  OHLB-OP1 
53 VATB-OP1  OHLC-OP1 
54 WALC-OP1  OHLP-OP1 
55 WANW-OP1  OHMV-IO1 
56 WISE-IO1  OHOV-OP1 
57 WIUW-IO1  OKHM-IO1 
58   OKOP-OP1 
59   ORUO-IO1 
60   PADV-OP1 
61   PATF-OP1 
62   PRLL-OP1 
63   SCOP-OP1 
64   TNDS-OP1 
65   TNET-OP1 
66   TNMS-OP1 
67   TXAD-IO1 
68   TXBC-IO1 
69   TXFW-IO1 
70   TXGC-OP1 
71   TXLG-IO1 
72   TXSA-OP1 
73   TXSB-OP1 
74   UNKN-OP1 
75   UTOP-OP1 
76   VAFH-IO1 
77   VAOP-OP1 
78   VATB-OP1 
79   WALC-OP1 
80   WANW-OP1 
81   WASH-IO1 
82   WISE-IO1 
83   WISL-IO1 
84   WIUW-IO1 
85   WVMS-OP1 
86   ZCAN-FOP 
87   ZFOR-FOP 
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Appendix C: Cold Ischemic Time Vs Distance 
 
Table C.1 Analysis for 0 - 5000 in range of 100 miles 
 
Analysis for 0 - 5000 in range of 100 miles    
Distance - Miles 
Mean 
CIT LCL UCL SD Var Range 
0 - 100 8.0399 7.9931 8.087 4.5655 20.8438 50 
100 - 200 9.2977 9.2149 9.38 4.398 19.3424 150 
200 - 300 9.8012 9.6868 9.916 4.5425 20.6343 250 
300 - 400 10.0359 9.8478 10.22 5.2455 27.5153 350 
400 - 500 10.1749 9.9574 10.39 4.867 23.6877 450 
500 - 600 10.3177 10.066 10.57 5.2922 28.0074 550 
600 - 700 10.8373 10.542 11.13 4.8056 23.0938 650 
700 - 800 11.1372 10.816 11.46 4.8368 23.3946 750 
800 - 900 10.8209 10.495 11.15 4.9589 24.5907 850 
900 - 1000 11.9619 11.467 12.46 5.2669 27.7402 950 
1000 - 1100 10.8845 10.425 11.35 4.7745 22.7959 1050 
1100 - 1200 11.6717 11.118 12.23 4.4073 19.4243 1150 
1200 - 1300 11.5631 10.887 12.24 5.8062 33.712 1250 
1300 - 1400 11.6803 10.831 12.53 5.2437 27.4964 1350 
1400 - 1500 12.3073 11.746 12.87 3.9215 15.3782 1450 
1500 - 1600 13.0943 12.239 13.95 5.6182 31.5642 1550 
1600 - 1700 13.3862 12.533 14.24 5.2145 27.191 1650 
1700 - 1800 13.096 12.307 13.89 3.8089 14.5077 1750 
1800 - 1900 15.0422 14.351 15.73 5.2262 27.3132 1850 
1900 - 2000 15.5607 14.483 16.63 5.563 30.947 1950 
2000 - 2100 14.1942 13.371 15.02 5.2225 27.2745 2050 
2100 - 2200 13.9505 12.719 15.18 6.2371 38.9014 2150 
2200 - 2300 13.2455 12.156 14.34 4.5704 20.8886 2250 
2300- 2400 14.3079 11.91 16.71 4.9756 24.7566 2350 
2400 - 2500 8.775 2.6667 14.88 3.8387 14.7356 2450 
       
Only 14 readings for distance between the transplant centers greater than 2500. 
       
Analysis for 0 - 500 miles in range of 50 miles    
Distance - Miles Mean LCL UCL SD Var Range 
0 - 50 7.7897 7.7351 7.844 4.6128 21.2779 25 
50 - 100 8.7992 8.7119 8.887 4.3447 18.8764 75 
100 - 150 9.247 9.1358 9.358 4.3716 19.1109 125 
150 - 200 9.4103 9.293 9.528 4.4444 19.7527 175 
200 - 250 9.6498 9.5067 9.793 4.434 19.6604 225 
250 - 300 9.96 9.7771 10.14 4.6427 21.5547 275 
300 - 350 9.7486 9.498 9.999 5.2697 27.7697 325 
350 - 400 10.3845 10.107 10.66 5.2251 27.3017 375 
400 - 450 10.262 9.9587 10.57 4.9757 24.7576 425 
450 - 500 10.0516 9.7451 10.36 4.7187 22.2661 475 
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Appendix C: (Continued) 
 
Table C.2 ANOVA Table for Patients Arrivals 
 
SUMMARY OUTPUT        
         
Regression Statistics        
Multiple R 0.8874623        
R Square 0.7875894        
Adjusted R 
Square 0.761038        
Standard Error 0.3801294        
Observations 10        
         
ANOVA         
  Df SS MS F 
Significance 
F    
Regression 1 4.2862407 4.28624 29.6629 0.000611    
Residual 8 1.1559871 0.1445      
Total 9 5.442227          
         
  Coefficients 
Standard 
Error t Stat P-value Lower 95% 
Upper 
95% 
Lower 
95.0% 
Upper 
95.0% 
Intercept 8.39059 0.24132 34.769 5.1E-10 7.83410 8.9470 7.83410 8.9470 
X Variable 1 0.00455 0.00083 5.44637 0.00061 0.00262 0.0064 0.00262 0.0064 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C.1 Arrival of MELD Patients / OPO 
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Appendix C: (Continued) 
 
Table C.3 ANOVA for Distance vs. CIT 
 
SUMMARY OUTPUT        
         
Regression Statistics        
Multiple R 0.7255        
R Square 0.5263        
Adjusted R 
Square 0.5057        
Standard 
Error 1.3935        
Observations 25        
         
ANOVA         
  Df SS MS F 
Significance 
F    
Regression 1 49.627 49.627 25.56 4.066E-05    
Residual 23 44.662 1.9418      
Total 24 94.289          
         
  Coefficients 
Standard 
Error t Stat 
P-
value Lower 95% 
Upper 
95% 
Lower 
95.0% 
Upper 
95.0% 
Intercept 9.3651 0.5577 16.791 2E-14 8.2113027 10.51882 8.211303 10.51882 
X Variable 1 0.002 0.0004 5.0554 4E-05 0.0011543 0.002753 0.001154 0.002753 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C.2 Distance vs. CIT 100 miles 
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